Comparing vedolizumab and infliximab for pediatric ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This study compares two biologic medicines, vedolizumab and infliximab, to see which works better for children with moderate to severe ulcerative colitis. It aims to find a more effective treatment to reduce symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 6 and 17 years old.
- The ulcerative colitis should be moderate to severe, not just mild.
- Your child must have tried at least one standard treatment (like steroids or immune-suppressing drugs) and it didn't work or caused problems.
- The disease must affect more than just the rectum.
- Your child cannot have been treated with certain biologic drugs (like vedolizumab, infliximab, or natalizumab) before.
- Your child must be up to date on vaccinations, and must not have had certain surgeries or serious neurological conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This Phase 3 study tests whether vedolizumab can help children with ulcerative colitis (UC) or Crohn’s disease (CD) who improved on earlier treatment. It focuses on kids who can stay off steroid medicines and follow study visits and safety rules.
This study is for children and teenagers with ulcerative colitis or Crohn's disease who have already completed a previous vedolizumab study and are doing well. It will look at the long-term safety and effectiveness of continuing vedolizumab treatment.
This study tests a medication called vedolizumab for people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to see how well it works in a regular community setting, and it may help control symptoms if other treatments haven't worked.
This program lets children and teenagers with ulcerative colitis or Crohn's disease continue receiving vedolizumab (a biologic medicine) through an IV if it's already helping them. It's for those who have no better treatment options and want to keep getting the same medicine.
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.